Fig. 1

Proteasomal inhibition does not influence enzalutamide-induced AR protein reduction. A Representative western blot to investigate the role of proteasomal inhibitors on the AR protein decreasing effect of Enzalutamide, hormone-sensitive PCa cells were treated with 1 nM R1881, 1 nM R1881 + 10 µM Enzalutamide, and 1 µM R1881 + 0.1 µM Bortezomib, Carfilzomib, or Epoxomicin. Ubiqitine was assessed for proteasomal activity. Androgen receptor (AR) levels were normalised to total protein stain (TPS) to assess changes in AR levels after treatment. Uncropped western blots are displayed in Supplementary Fig. 2A. B Densitometry of ubiquitin levels relative to TPS. Relative expression levels compared to CTRL after treatment were shown as mean ± SD of four independent experiments. C Densitometry of AR protein levels relative to TPS. Relative expression levels compared to CTRL after treatment were shown as mean ± SD of four independent experiments